Podcasts

E-Books

Videos

Articles

Business & Practice

Tony Hagen is senior managing editor for The Center for Biosimilars

In the EU-5 group of countries, biosimilar awareness is poor, hindering uptake of these potentially cost-saving medicines, a white paper states. 

Samsung Bioepis Examines European Awareness of Biosimilars

Samsung Bioepis hopes to gain regulatory approval for a denosumab biosimilar referencing Prolia. The trial will focus on women with postmenopausal osteoporosis.  

Samsung Bioepis Initiates Phase 3 Trial for Denosumab Biosimilar

Two studies of trastuzumab biosimilars have improved understanding of these medicines as monotherapy and in combination with other agents in metastatic breast cancer.

Trastuzumab Biosimilar With PIK3CA Inhibitor Shows Efficacy in Advanced Breast Cancer

A high overall response rate of 93% was observed for patients with immune thrombocytopenic purpura who received romiplostim biosimilar. 

Romiplostim Biosimilar Study Demonstrates Safety, Efficacy in Real-World India Population

The wearable injector has a failure rate that adds hospitalization costs; therefore, biosimilar pegfilgrastim may hold cost advantages, investigators conclude. 

Investigators: Biosimilar Pegfilgrastim Has Advantages Over Wearable Injector

Biosimilar suffixes were intended to help with pharmacovigilance, but they are not widely understood. 

Poll: How Much Do You Know About Biosimilar Suffixes?

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

Minute differences between biosimilars and reference products are not considered “clinically meaningful,” but these differences are exploitable when it comes to addressing allergies related to originator products.

Providers Exploit Minor Differences Between Innovator Drugs and Biosimilars

Pfizer aims to begin marketing Nyvepria in the European Union in the first quarter of 2021.

European Commission Approves Pfizer's Pegfilgrastim Biosimilar

Bincy P. Abraham, MD, MS, AGAF, FACG, is a professor of Clinical Medicine at Houston Methodist Academic Institute. She is also the distinguished professor and director of the Fondren Inflammatory Bowel Disease Program at the Underwood Center for Digestive Disorders and director of Gastroenterology Fellowship Program at Houston Methodist Hospital.

Bincy P. Abraham, MD, explains that even when payers allow coverage for biosimilars, providers may still be hesitant to use them. 

Opinion: Embrace the Era of Next-Generation Biologics

Kathy Oubre, MS, chief operating officer at the Pontchartrain Cancer Center in Louisiana, discusses the value of biosimilars. 

Practice